Abstract Library

#4570 Diagnosis of carcinoid heart disease continues to be late delayed

Introduction: Carcinoid heart disease (CHD) is a serious complication of neuroendocrine tumours. It affects patients with carcinoid syndrome and results from fibrotic deposits on the heart valves. It significantly impacts patient prognosis.

Conference:

Presenting Author:

Authors: Sharma J, Shah T, Coldham C, Vickrage S, Rehman Z,

Keywords: carcinoid syndrome, neuroendocrine tumour, carcinoid heart disease, symptoms, presentation, echocardiogram, heart valves,

#4101 Pulmonary neuroendocrine tumors – Symptomatology, tumor characteristics, treatment strategies, and long-term outcomes in 37 Patients

Introduction: Pulmonary Neuroendocrine Tumors (NET) constitute a complex group of diseases with varied clinical manifestations and no definitive diagnostic and treatment guidelines.

Conference:

Presenting Author: Krishna B

Authors: Jain D, Eshpuniyani P, Deshpande R, Sharma S, Krishna B,

Keywords: epidemiology, pulmonary NET, lobectomy, prognosis,

#2163 Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Carcinomas: Case Series

Introduction: High-grade neuroendocrine carcinomas (NECs) possess inevitable tendencies to metastasise and hold poor prospects of survival. Patients with neuroendocrine tumours who progress after medical management can be treated with peptide receptor radionuclide therapy (PRRT), on the proviso that there is positive uptake on 68Ga-DOTATATE PET/CT imaging. Despite this, a proportion of patients who exhibit positive imaging respond poorly to therapy. Management of NECs is currently limited; evidence for treating NECs with PRRT is scarce.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Butt S, Evans J, Sharma R,

Keywords: neuroendocrine, carcinoma, tumours, PRRT,

#457 Comparison of Transarterial Liver-Directed Therapies (LDT) for Low-Grade Metastatic Neuroendocrine Tumors (mNETs)

Introduction: Transarterial LDT can ameliorate symptoms and improve time to tumor progression (TTP) in mNETs.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Engelman E, Leon-Ferre R, Naraev B, Sharma N, Sun S,

Keywords: hepatic, artery, embolization, chemoembolization, radioembolization, neuroendocrine, tumors,

#439 Chromogranin A (CgA) and Pancreastatin (PcSt) as Predictors of Peptide Receptor Radionuclide Therapy (PRRT) Outcomes in Patients with Metastatic Well-Differentiated Neuroendocrine Tumors (mNETs)

Introduction: CgA and PcSt are widely used in assessing response to treatment in mNETs.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Sharma N, Naraev B, Engelman E, Zimmerman M, Bushnell D,

Keywords: pancreastatin, chromogranin, peptide, receptor, radionuclide, therapy, PRRT, neuroendocrine, tumors,